We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Rituximab as First-Line and Maintenance Therapy for Patients With Small Lymphocytic Lymphoma and Chronic Lymphocytic Leukemia

Mar 1, 2002
Volume: 
16
Issue: 
3
  • Leukemia & Lymphoma

Although patients with small lymphocytic lymphoma and chronic lymphocytic
leukemia (SLL/CLL) have CD20 expression on malignant lymphocytes, response rates
with standard rituximab (Rituxan) courses in refractory patients have been low.
However, our initial experience with first-line therapy produced responses in 15
of 23 patients with SLL. We have therefore expanded our experience, and have now
treated a total of 68 previously untreated patients with either SLL (37
patients) or CLL (31 patients) with single-agent rituximab.

All patients received rituximab (375 mg/m² weekly × 4); patients with
objective response or stable disease at reevaluation (6 weeks) continued
maintenance courses of rituximab, using a standard 4-week schedule, every 6
months for a maximum of four courses. Eligibility requirements included stage
III or IV SLL or CLL, no previous therapy, Eastern Cooperative Oncology Group
performance status of 0 to 2, no life-threatening signs/symptoms, and informed
consent.

Between April 1998 and June 2001, 68 patients were treated in two sequential
multicenter, community-based clinical trials; 66 have been evaluated for
treatment response. Patient characteristics included median age, 66 years
(range: 38-89 years); B symptoms, 13 patients (23%); white blood cell count ³
50,000 cells/mL, 19 patients (28%). At week 6, 33 of 66 evaluable patients (50%)
had objective responses (9% complete response rate), and 32 additional patients
(48%) had stable disease. Twenty-seven patients remain on therapy and are
receiving maintenance rituximab courses. Median follow-up of the initial 24
patients is 26 months; in these patients, median progression-free survival was
35 months. Toxicity with this treatment program was limited to the typical
rituximab-related infusion reactions; only one patient had reversible grade 3/4
toxicity.

CONCLUSION: Rituximab is highly active as first-line therapy for CLL/SLL,
producing substantially higher responses than have previously been seen in
patients with refractory disease. Further follow-up is necessary to assess the
duration of response and the benefit of maintenance treatment with rituximab.
Data correlating the response rate with surface CD20 antigen density will also
be presented. Rituximab should be evaluated as part of first-line combination
therapy for patients with CLL/SLL.

Click here to read Dr. Bruce Cheson's commentary on this abstract.

Related Articles

  • BCR-ABL1 Levels Can Predict Sustained Deep Molecular Response in CML
  • Rituximab Does Not Improve Outcomes in Primary CNS Lymphoma
  • Adding Brentuximab to BEACOPP Promising in Relapsed Hodgkin Lymphoma
  • Integrating Genetics, MRD Improves Risk Stratification in Childhood ALL
  • Breast Implants Linked to Anaplastic Large-Cell Lymphoma

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.